Szela Mary T
SEC CIK 1410289 · EDGAR
BoughtSold
Most active insiders at TLSI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Stansky Michael P | Dir | $3.01M | — |
| 2 | Szela Mary T | CEO, Pres, Dir | $227.8K | $79.4K |
| 3 | Wahlstrom Mats | Dir | $151.8K | — |
| 4 | Valle William | Dir | $125.0K | — |
| 5 | Gordon Gary B. | Dir | $64.6K | — |
| 6 | Patience David | CFO | $32.2K | — |
| 7 | Marshak Richard | Chief Commercial Off | — | $15.7K |
| 8 | Stevens Jennifer | Chief Regulatory Off | — | $14.5K |
| 9 | Devlin Jodi | Chief of Clinical Ops | — | $13.2K |
| 10 | Cox Bryan F. | Chief of Research | — | $13.1K |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 16:06 | 2026-06-30 | ABSI | Absci Corp | Szela Mary T | Dir | P - Purchase | $11.54 | +12.9K | 21.3K | +154% | +$148.9K | |
| 2026-07-01 16:04 | 2026-06-30 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO, Pres, Dir | A - Grant | $3.87 | +3,990 | 1.08M | +0.4% | +$15.4K | |
| DA | 2026-06-15 20:40 | 2026-06-04 | ABSI | Absci Corp | Szela Mary T | Dir | A - Grant | $0.00 | +8,400 | 8,400 | New | $0 |
| D | 2026-06-08 21:59 | 2026-06-04 | ABSI | Absci Corp | Szela Mary T | Dir | A - Grant | $0.00 | +10.1K | 10.1K | New | $0 |
| 2026-05-18 16:42 | 2026-05-15 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO, Pres, Dir | P - Purchase | $2.59 | +39.7K | 1.07M | +4% | +$102.8K | |
| M | 2026-03-20 | 2026-03-11+ | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO, Pres, Dir | S - Sale | $3.91 | -20.3K | 768.9K | -3% | -$79.4K |
| 2026-02-23 | 2026-02-23 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO, Pres, Dir | P - Purchase | $4.10 | +30.5K | 773.3K | +4% | +$125.0K | |
| DM | 2025-11-25 | 2024-02-13+ | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO, Pres, Dir | A - Grant | $0.00 | +550.0K | 317.8K | New | $0 |
| 2025-02-19 | 2025-02-18 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +21.1K | 465.3K | +5% | $0 | |
| M | 2025-01-31 | 2025-01-29+ | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.15 | +10.0K | 439.2K | +2% | +$51.8K |
| DM | 2025-01-29 | 2025-01-27+ | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.27 | +9,542 | 429.5K | +2% | +$50.3K |
| D | 2025-01-29 | 2025-01-27 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +40.0K | 424.7K | +10% | $0 |
| M | 2024-09-13 | 2024-09-12+ | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $5.09 | +14.8K | 384.7K | +4% | +$75.4K |
| 2024-09-12 | 2024-09-10 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | P - Purchase | $4.97 | +5,000 | 369.9K | +1% | +$24.9K | |
| D | 2024-02-14 | 2024-02-13 | TLSI | TriSalus Life Sciences, Inc. | Szela Mary T | CEO AND Pres, Dir | A - Grant | $0.00 | +84.9K | 364.9K | +30% | $0 |
Purchase Sale Sale after option exercise All abbreviations